Biopolymed Inc.

Viromed Co., Ltd.

Angiolab, Inc.

Engene, Inc.

Myung-Ok Park

Sang-Wook Kang

Min-Young Kim

Choun-Ki Joo

Myung Suk Kim

Yu-Kyoung Oh

Jun-Sub Choi

Byung-Young Park

Chang-Hee Moon

Sang Myoung Noh

Seong-Hyun Ho

Yuni Jung

Myoung-Suk Kim

Sung Sik Bang

Kyung-A Kim

Sung-Sik Bang

Bon-Hong Min

Boe-Gwun Chun

The present invention provides for biopolymer conjugates of an IL-11 analog (mIL-11) and a biocompatible polymer. The mIL-11 of the invention displays an enhanced resistance to acidolysis and shows increased stability as compared to rhIL-11. The conjugates of the present invention are characterized by a longer serum half-life and exhibit essentially no loss of activity as compared to the corresponding unconjugated mIL-11.

Biopolymer conjugates comprising an interleukin-11 analog

The present invention relates to a conjugate of chitosan and polyamine polymer that is useful for transferring a desired gene medicine into cells, and a method for preparing the same. In particular, the present invention relates to a double conjugate that is prepared by 1 in king poly-L-arginine to low molecular weight chitosan or triple conjugate that is prepared by additionally linking polyethylene glycol (PEG) to the double conjugate, and a method for preparing the same. The chitosan based cationic polymer conjugate of the present invention forms a complex with negatively charged gene medicine such as plasmid DNA and small interfering RNA to efficiently transfer the desired gene medicine into cells with low cytotoxicity. Accordingly, the conjugate can be used as an effective delivery system for in vivo administration of gene medicine.

Chitosan based polymer conjugate and a method for producing the same

The present invention relates to a siRNA which targets mRNA of the NF-Kappa B p105 gene to cause its degradation by RNAi induction. In addition, the present invention provides a pharmaceutical composition for the treatment of diseases associated with aberrant cell proliferation and migration, comprising the siRNA and delivery vehicle capable of intracellular delivery of the same.

siRNA of NF-kB p105 for inhibiting cell proliferation and migration and a composition comprising same

The present invention relates to a conjugate of a biocompatible polymer and a G-CSF bonded through a thiol group of a dysteine residue in G-CSF at a 1:1 molar ratio, and methods of preparation thereof.

Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF

The present invention relates to a pharmaceutical composition for inhibiting angiogenesis which comprises arginine deiminase as an active ingredient, where the arginine deiminase, obtained fromor prepared by a genetic recombination technique, may be conjugated to an activated polymer to lower its immunogenecity and increase its life time. The pharmaceutical composition of the present invention exhibits an excellent inhibitory activity against angiogenesis.

Pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis

Growing community of inventors

Seoul, South Korea

Myung-Ok Park